Labcorp's PGDx elio® tissue complete CDx has received FDA approval as a companion diagnostic to identify advanced melanoma patients with specific BRAF mutations. This test helps clinicians determine which patients may benefit from targeted BRAF and BRAF/MEK inhibitor therapies, improving treatment options for a deadly skin cancer with low survival rates. The test is scalable for use in hospitals and labs, supporting broader access to personalized cancer care. Labcorp continues to expand its precision medicine portfolio with this approval, enhancing patient access to advanced molecular diagnostics.
Ether (ETH) trading volume on the Hyperliquid platform reached approximately $1.1 billion over a 24-hour period ending October 11, surpassing Bitcoin (BTC) trading volume of $805 million by about $295 million. This indicates a stronger trading intere...
On October 11, a Hyperliquid whale maintained a 1,000 Bitcoin long position valued at approximately $83.04 million, with an unrealized profit of about $10.27 million. The position used 3x cross margin and had an average entry price of $72,771, yieldi...
Vanguard's VYM ETF offers retirees significantly higher quarterly income with a 2.35% yield compared to VIG's 1.51%, generating about $8,400 more annually on a $1 million investment. However, VIG has outperformed VYM in total returns over the past de...
Bitcoin is stable around $83,000 despite a 2% weekly drop, while major altcoins like Ethereum, Solana, and XRP face sharper declines of 5-10%. ETF outflows, rising US interest rates, and geopolitical tensions are pressuring the market. Key upcoming e...
On October 9, 2026, ARK Invest's actively managed ETFs reduced holdings in crypto-related assets like the ARK 21Shares Bitcoin ETF and Robinhood Markets, while selling SpaceX shares and DraftKings. Meanwhile, they increased positions in technology st...
